HBW Advisory Services LLC Invests $509,000 in Invesco Pharmaceuticals ETF (NYSEARCA:PJP)

HBW Advisory Services LLC acquired a new stake in Invesco Pharmaceuticals ETF (NYSEARCA:PJP) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 5,851 shares of the company’s stock, valued at approximately $509,000. HBW Advisory Services LLC owned about 0.17% of Invesco Pharmaceuticals ETF at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in PJP. GAMMA Investing LLC purchased a new stake in Invesco Pharmaceuticals ETF in the 2nd quarter valued at $40,000. International Assets Investment Management LLC purchased a new stake in shares of Invesco Pharmaceuticals ETF in the second quarter valued at about $66,000. Geneos Wealth Management Inc. increased its position in Invesco Pharmaceuticals ETF by 91.6% during the first quarter. Geneos Wealth Management Inc. now owns 2,050 shares of the company’s stock worth $164,000 after purchasing an additional 980 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new position in Invesco Pharmaceuticals ETF during the first quarter worth about $213,000. Finally, PFG Advisors acquired a new position in Invesco Pharmaceuticals ETF in the 1st quarter valued at about $220,000.

Invesco Pharmaceuticals ETF Stock Performance

Shares of NYSEARCA PJP traded up $0.57 during midday trading on Friday, reaching $86.38. 2,815 shares of the stock were exchanged, compared to its average volume of 16,028. The stock has a market capitalization of $292.84 million, a P/E ratio of 21.48 and a beta of 0.61. The company has a 50 day simple moving average of $86.53 and a 200 day simple moving average of $82.46. Invesco Pharmaceuticals ETF has a twelve month low of $67.75 and a twelve month high of $89.34.

Invesco Pharmaceuticals ETF Company Profile

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.